Foekens J A, Sieuwerts A M, Stuurman-Smeets E M, Peters H A, Klijn J G
Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Br J Cancer. 1993 Feb;67(2):232-6. doi: 10.1038/bjc.1993.45.
The polyanionic compound suramin can inhibit the proliferation of cells of various origin, including from breast cancer. We have studied the effects of suramin on cell cycle kinetics and distribution of MCF-7 human breast cancer cells in vitro. It was found that both under serum-containing and serum-free culture conditions, and in the absence or presence of oestradiol or insulin-like growth factor-1, prolonged exposure (> or = 48 h) to suramin caused an accumulation of surviving cells in the G2/M-phase of the cell cycle. At a concentration of more than 100 micrograms ml-1 suramin significantly inhibited cell proliferation. The observed effects of suramin on breast cancer cells in vitro, i.e. antiproliferative effects and accumulation of cells in the G2/M-phase of the cell cycle, may have beneficial consequences in the application of treatment strategies based on a combination of suramin with cell cycle specific drugs or radiation therapy.
多阴离子化合物苏拉明能够抑制包括乳腺癌细胞在内的各种来源细胞的增殖。我们研究了苏拉明对MCF-7人乳腺癌细胞体外细胞周期动力学及分布的影响。结果发现,无论是在含血清和无血清培养条件下,以及在有或无雌二醇或胰岛素样生长因子-1的情况下,长时间暴露(≥48小时)于苏拉明会导致存活细胞在细胞周期的G2/M期积累。当苏拉明浓度超过100微克/毫升时,可显著抑制细胞增殖。苏拉明对乳腺癌细胞的体外作用,即抗增殖作用以及细胞在细胞周期G2/M期的积累,可能对基于苏拉明与细胞周期特异性药物联合应用或放射治疗的治疗策略具有有益影响。